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Abstract
Objectives: To assess the effect of local infiltration of anesthetic to the vaginal cuff on postoperative 
pain after laparoscopic hysterectomy.
Methods: A single-center, randomized trial. Women assigned to laparoscopic hysterectomy were 
randomly divided into two groups. In the intervention group (n=41) the vaginal cuff was infiltrated 
with 10 ml of ropivacaine (7.5 mg/ml) at four points, in addition to trocar-site anesthesia. In the 
control group (n=40) only trocar incisions were infiltrated with local anesthetic. The primary 
outcomes were postoperative opioid (oxycodone) use and postoperative pain in Visual Analog 
Scale (VAS). Secondary outcomes were emesis, bleeding, operative time, time to discharge and 
complications.
Results: The number of patients with minimal pain i.e. VAS scores for pain below 3 was significantly 
higher in the intervention group than in the control group (17 vs. 8, p=0.04). Otherwise, there were 
no significant differences between the groups in VAS scores for pain, the use of opioids or in any 
other variables.
Conclusion: Injection of local anesthetic into the vaginal cuff along with trocar sites analgesia did 
not affect the use of oxycodone, but increased the number of women experiencing only minor pain 
after laparoscopic hysterectomy. Local anesthesia of the vaginal cuff was feasible and safe.
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Introduction
Laparoscopy is the preferred surgical approach in gynecologic surgery because it diminishes 
pain and enhances recovery. Laparoscopic hysterectomy is one of the most common gynecological 
procedures in Finland: 44% of the 5279 hysterectomies performed in 2006 were vaginal, 32% 
laparoscopic and 24% abdominal [1,2]. Patients undergoing the laparoscopic approach still require 
opioid analgesics in the early postoperative period, which increases the risk of opioid-related 
side effects, such as vomiting, nausea, constipation and sedation. These symptoms may delay 
mobilization, home discharge and recovery. Opioid-free or opioid-reduced analgesia are used to 
reduce postoperative pain and opioid-related side effects in multimodal regimens [3-6]. The one 
of basic principles of ERAS (Enhanced Recovery after Surgery) is a focus on regional anesthetic 
and non opioid analgesic approaches [7]. Local analgesia/anesthetic infiltration is effective for the 
early treatment of postoperative pain in various surgical procedures [8-12]. Infiltration relieves 
postoperative pain and reduces opioid use after abdominal/and vaginal hysterectomy genital 
prolapse surgery and gynecologic laparoscopic surgery [8-11,13]. However, vaginal cuff infiltration 
with a local anesthetic for pain relief after laparoscopic hysterectomy has not been described or 
assessed. The present randomized controlled study tested the hypothesis that local infiltration of the 
vaginal cuff at the end of laparoscopic hysterectomy could decrease postoperative pain and opioid 
use.
Materials and Methods
This randomized controlled, open-label trial was performed at department of Obstetrics and 
Gynaecology, Helsinki University Hospital between November 2014 and May 2015. All gynaecologic 
surgery in the Helsinki metropolitan region is centralised in this tertiary referral hospital. Women 
scheduled for laparoscopic hysterectomy with salpingectomy or salpingo-oophorectomy for benign 
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conditions or a malignant condition that only required simple 
hysterectomy (e.g., cervical in situ carcinoma, low-risk endometrial 
cancer or prophylactic hysterectomy with an inherited risk of genital 
cancer) were assessed for eligibility. All candidates were interviewed 
at the preoperative visit to obtain a detailed general, gynaecologic 
and operative history. A complete physical and gynaecological 
examination, including Body Mass Index (BMI) measurement and 
transvaginal ultrasonography, were performed. The exclusion criteria 
were endometriosis, contraindications to any of medications used 
in the study (oxycodone, ketoprofen, or paracetamol), and language 
difficulties (inability to understand and speak Finnish or Swedish). 
The criterion for inclusion was a uterine size less than uterine size 
at 14 weeks of pregnancy. Participants were given information 
orally and in writing, and a signed consent form was obtained from 
all women. Participants were randomly allocated into two groups: 
an intervention group (IG; n=41) that received local anaesthetic 
infiltration to the vaginal cuff, and a control group (CG; n=40) that did 
not receive vaginal cuff infiltration. The randomization of participants 
into their respective groups was performed using a computer-
generated randomization program. The personnel responsible for 
generating the randomization list and sealing the envelopes did 
not participate in the allocation. The allocation cards were sealed 
in opaque, sequentially numbered envelopes. A surgeon opened 
the envelopes in the operating room prior to surgery. All surgeries 
were performed under general anaesthesia. The anaesthesiology 
protocol and use of local anesthetics were standardized. Each patient 
received 1 g paracetamol as premedication and antibiotic prophylaxis 
at induction (cefuroxime, 1.5 g or clindamycin, 600 mg in cases of 
allergy). Standard monitoring was used in the operating theatre. 
Anesthesia was induced and maintained with a controlled infusion 
of propofol and remifentanil. Tracheal intubation was facilitated 
with rocuronium. Patients were ventilated with a mixture of oxygen 
and air. The stomach was always aspirated. All patients received 
dexamethasone (5 mg) at the start of anesthesia and ondansetron 
(4 mg) with droperidol (0.1 mg/10 kg) at the end of surgery to prevent 
postoperative emesis. Each patient also received fentanyl (1 mg/kg) 
and ketoprofen (100 mg) at the end of the procedure for pain control. 
Patients were placed in the lithotomy position for the standardized 
laparoscopic procedure. A uterine manipulator (Valtchev Uterine 
Mobilizer, Conkin surgical instruments, Vancouver, Canada) was 
used to expose the uterus and pelvic structures. Pneumoperitoneum 
was created using a Veress needle (Mock Medical, Milford, USA) 
through the umbilicus, and a 10 mm umbilical trocar was inserted for 
optics. Three 5 mm trocars were inserted in the left and right para-
median regions and the suprapubic region under direct visualization. 
Bipolar cautery was performed to coagulate vessels, and scissors 
were used to dissect tissue. The uterus and fallopian tubes, with or 
without ovaries, were detached, circular colpotomy was performed, 
and the uterus was removed through the vagina. The vaginal cuff was 
closed using a continuous vertical Biosyn 2 to 0 (Covidien, Dublin, 
Ireland) suture vaginally. In the intervention group the vaginal cuff 
was infiltrated with 10 ml of ropivacaine (7.5 mg/ml) at four points 
around the wound in equal 2.5 ml volumes, 4 mm to 5 mm deep. 
In both groups the fascia of the 10 mm port and all skin incisions 
were closed using absorbable sutures. Five milliliters of ropivacaine 
(20 ml in total, 7.5 mg/ml) was infiltrated into each trocar incision 
between the skin and fascia in both groups. A Foley catheter was left 
in place until the next morning, but no abdominal drains were used. 
Postoperative pain was treated using intravenous or intramuscular 
oxycodone, and the amount of medication was recorded. Patients also 
received ibuprofen (600 mg) and paracetamol (1 g) three times daily, 
which they continued at home. The use of oxycodone was liberal. The 
women were asked to scale their pain, and they received oxycodone 
(3 mg) if they reported a VAS score >5 in the post-anesthesia care 
unit and surgical ward. Patients recorded the severity of incisional 
pain using VAS score (0 indicated no pain, and 10 indicated 
unbearable pain) at 1,3,6,12 and 24 h after surgery. VAS-rating of 
Variable Intervention group  (n=41) Control group (n=40)
Age (years) 56 (48-66) 58 (45-69)
BMI (kg/m2) 27 (22-31) 25 (23-29)
Painkiller chronic use 4 (9%) 1 (2%)
Previous abdominal surgery 27 (66%) 21 (53%)
ASA physical status
I    A normal healthy patient 10 (24%) 17 (43%)
II  A patient with mild systemic disease 24 (59%) 17 (43%)
III A patient with severe systemic disease 7 (17%) 6 (14%)
Nulliparous 9 (22%) 8 (20%)
Previous vaginal delivery 32(78%) 32 (80%)
Table 1: Demographics of the women undergoing laparoscopic hysterectomy.
Data are presented as median (IQR) or n (%); ASA: American Society of Anesthesiologist
Figure 1: Flow chart of study randomization.
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<4 correspond to mild pain, 4 to 6 to moderate pain, and 7 to 10 
to severe pain [14]. The operative time, emesis, amount of operative 
bleeding, uterus weight and complications were retrieved from 
patient files. The length of hospital stay was counted from the end of 
surgery until discharge. The local Ethics Committee of Helsinki and 
Uusimaa district approved the study design (98/13/03/03/2014/2). 
This study was also registered at clinicaltrials.gov as NCT02767544 
retrospectively.
Power calculation
The size of the sample was estimated from previous publications. 
Based on earlier data from our clinic we assumed that the need 
for oxycodone would be 30 mg within 24 hours after laparoscopic 
hysterectomy [15-17]. Vaginal wound infiltration with local 
anaesthetic was estimated to reduce the need of oxycodone to 10 mg 
(SD 15). The study would require 37 patients per group with 80% 
power (a=0.05) using a two-sample t-test. A 10% drop-out rate was 
assumed, and 40 patients were needed in each group.
Statistical analysis
All analyses were performed using SPSS software, version 20 
(IBM SPSS Inc., IL, and USA). Data are presented as medians and 
interquartile ranges (IQRs) or n (%). Differences in continuous 
variables were analyzed using the Mann-Whitney U-test for skewed 
data. Chi-square or Fisher’s exact tests were used for independent 
nominal data where appropriate. Statistical significance was defined 
as p<0.05. The 95% Confidence Interval (CI) for differences of 
proportions were calculated using new combe’s method.
Results
The eligibility of 105 women was assessed for this trial. Nineteen 
women were excluded because they did not fulfill the inclusion 
criteria (four did not speak Finnish or Swedish, six had medical 
contraindications and nine declined the invitation to participate). 
Eighty-six women were randomized (n=43 per group). There were 
two drop-outs in the intervention group (protocol violation) and 
three drop-outs in the control group (two laparoscopy converted 
to laparotomy and one protocol violation). Therefore, 81 cases 
were analyzed (Figure 1). Table 1 describes the basic demographic 
characteristics of these women, and Table 2 presents the indications 
for hysterectomy. There were no significant demographic differences 
between groups in the age, BMI, painkiller chronic use, previous 
abdominal surgery, ASA physical status and parity. The total dose 
of oxycodone used was equal (10 mg [6 to 16 mg] and 10 mg [6 to 
17 mg]; p=0.63) in the intervention and control groups, respectively 
(Table 3). VAS scores for pain at 1,3,6,12 and 24 h after surgery and 
median maximal pain did not differ statistically significantly between 
groups. No differences in the operative bleeding, operative time, time 
to discharge, postoperative emesis or major complications between 
the study groups were found. The mean uterine weight was similar 
in the two groups (81 g vs. 81.5 g; p=0.82). Morcellation was not 
used for uterine removing. However, all asked VAS scores for pain 
at 1,3,6,12 and 24 h postoperatively were less than 3 during the entire 
postoperative study period in 17 patients in the intervention group 
and 8 patients in the control group, which was statistically significant 
(p=0.04). No complications (allergic reaction, IV (Intravenous) 
injection or the use of the anesthetic itself) were related to the vaginal 
cuff infiltration with local anesthetic.
Discussion
To our knowledge, this report is the first study of the effect 
of vaginal cuff infiltration with local anesthetic in laparoscopic 
hysterectomy. We performed a randomized study to evaluate the 
feasibility and safety of local vaginal anesthesia to relieve postoperative 
pain. Minimizing the use of opioids supports enhanced recovery 
and discharge and prevents opioid-related side effects. There was no 
difference in the total use of oxycodone. However, postoperative local 
infiltration of the vaginal cuff with abdominal trocar incision analgesia 
increased the number of women who experienced only minor 
postoperative pain. No difference in the use of oxycodone was found 
between the groups, and the quantity of opioids used was equally 
minimal. A recent observational study investigated the effect of pain 
medication after laparoscopic hysterectomy, without local anesthesia, 
but using a delicate surgical technique [18]. VAS pain scores in 
their study were low (mean VAS score <4), and the investigators 
discharged patients five hours after surgery. Paracetamol, naproxen 
and tramadol were used for pain medication in their study, but the 
quantities of these medications were not reported. Their laparoscopic 
technique was quite similar to ours in all other respects, except 
the suturing of the vaginal cuff. They sutured the vagina and the 
uterosacral ligaments laparoscopically, whereas we did it vaginally. 
Intervention group (n=41) Control group (n=40) p-value
Atypical adenomatous hyperplasia 12 (29%) 14 (35%) 0.58
In situ cervical carcinoma 7 (17%) 7 (17%) 0.96
Low-risk endometrial cancer 5 (13%) 5 (13%) 0.97
Menorrhagia 13 (32%) 11 (28%) 0.68
Adenomyosis 1 (2%) 2 (5%) 0.54
Prophylactic hysterectomy (increased inherited risk of 
genital cancer) 3 (7%) 1 (2%) 0.32
Table 2: Indications for laparoscopic hysterectomy.
Figure 2: Ropivacaine injection sites around vaginal incision.
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The operative time was longer in our study, possibly because of the 
teaching role of our hospital. A team consisting of an expert surgeons 
and a trainee assistant performed all procedures. VAS scores were 
low in both studies despite the methodological differences. Vaginal 
local anesthesia in our study increased the number of patients with 
VAS scores less than 3 during the first 24 postoperative hours without 
adverse effects. Vaginal cuff anesthesia does not significantly lengthen 
operative time and as far as costs are concern, it is cheap. Ropivacaine 
was used because of its safety profile, which is superior to bupivacaine 
(Figure 2). Ropivacaine exhibits fewer cardiovascular and central 
nervous system toxicities than bupivacaine in healthy volunteers. 
Ropivacaine exhibits efficacy that is generally similar to the same 
dose of bupivacaine in postoperative pain relief compared pre-
incision infiltration of extended-release liposomal bupivacaine with 
0.25% bupivacaine for port-site analgesia in traditional and robotic 
laparoscopic hysterectomy [19,20]. Pain in the liposomal bupivacaine 
group was slightly lower, but they found no difference in opioid use or 
measures of function. The strengths of our study were the randomized 
nature of the trial, the standardized protocols of the anesthesia and 
surgical technique, the strict follow-up, documentation of pain and 
medication use and data of pain during 24 h after surgery. However, 
there are some limitations to our study. The first limitation is the 
estimation of the amount of oxycodone needed for postoperative 
pain. A re-calculation of the power analysis showed that a new 
study would need thousands of women in order to show a statistical 
difference in the need of oxycodone, if there is any. However, the 
unexpectedly low need for oxycodone could not be predicted. The use 
of oxycodone was lower than expected compared to earlier studies 
performed in our clinic [16,17]. Our current use of concomitant local 
anesthesia at abdominal trocar incision sites may partially explain 
the lower need for postoperative oxycodone in this study, in contrast 
to earlier studies in the same department. The similar and low use 
of oxycodone is likely to limit the conclusions that may be drawn. 
Another limitation is the frequency of eliciting VAS scores for pain, 
which were collected at 1,3,6,12 and 24 h postoperatively. These 
scores could have been recorded more frequently. The time intervals 
of pain intensity reporting reflect normal clinical practice. However, 
no complications were related to the use of vaginal cuff infiltration.
Variable Intervention group n=41 Control group n=40 p
Oxycodone (mg) 10 (6-16) 10 (6-17) 0.63
VAS 1h 2 (0-2) 3 (0-4) 0.76
VAS 3h 1 (0-2) 0 (0-3) 0.68
VAS 6h 0 (0-2) 1 (0-2) 0.16
VAS 12h 0 (0-1) 0 (0-1) 0.88
VAS 24h 1 (0-3) 1 (0-2) 0.96
VAS < 3 continuously for 24h 17 (41.5%) 8 (20.0%) 0.04*
VAS max 3 (2 to 4) 4 (2-4) 0.31
Postoperative emesis 5 (12) 5 (13) 0.97
Operative time (min) 100 (70-133) 115 (80-125) 0.41
Bleeding (ml) 50 (0-200) 100 (0-200) 0.793
Major complication 0 0 n. s.
Time to discharge (hours) 22.25 (20.75-24.00) 22.25 (21.00-23.95) 0.97
Uterine weight (g) 81 (60-134) 81.5 (57-146) 0.82
Table 3: Use of oxycodone, pain (VAS scores), operative time, bleeding and time to discharge among the women undergoing laparoscopic hysterectomy.
*Difference 21.5, 95% Confidence Interval 1.3 to 39.4); Data are presented as median (IQR) or n (%)
Conclusion
The present single-centre randomized study demonstrated 
that vaginal cuff infiltration with local anesthetic, concurrently 
with abdominal trocar incision analgesia, was feasible and safe 
for postoperative pain relief. All women in this study required 
low quantities of postoperative oxycodone. Vaginal injection of 
ropivacaine at the end of laparoscopic hysterectomy increased the 
amount of women who experienced only minimal postoperative 
pain for the first 24 h after surgery, with no impairments in surgical 
outcome.
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